ArticleJournal of trauma and injury2025
Autologous transfusion of hemothoraces in resuscitation after thoracic trauma: a narrative review.
Article in Journal of trauma and injury, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic hemothoraces represent a readily available, normothermic, and ABO-compatible source of blood. As a resuscitation fluid, pleural blood presents a reduced risk of transmissible disease and hemolytic transfusion reactions, and it minimizes patient exposure to the storage lesion that affects allogeneic blood products. Pleural blood therefore retains more physiological concentrations of electrolytes and 2,3-diphosphoglycerate when compared to packed red blood cells. However, pleural blood also has a lower oxygen-carrying capacity than packed red blood cells and is largely depleted of coagulation factors. Yet, due to the presence of tissue factor and other proinflammatory mediators, it may paradoxically increase clot formation once transfused. Uncertainty remains regarding the clinical relevance of the supranormal levels of proinflammatory mediators and the effects of autotransfusion on coagulation in vivo. There is now a body of evidence suggesting that autotransfusion reduces the requirement for donor blood products, and small studies have not identified any signals of harm; however, any positive or negative effects on patient outcomes are yet to be conclusively demonstrated. Centers with access to a robust supply of allogeneic donor blood should continue with standard care until more comprehensive research is conducted to clarify both the clinical benefits and risks of autotransfusion. Nonetheless, autotransfusion retains a role in cases where there is a contraindication to allogeneic transfusion, and in low-resource centers where safe and reliable access to donor blood products is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.